INDIANAPOLIS--Eli Lilly has licensed Pangea's bioinformatics software, including the GeneWorld application, GeneThesaurus data subscription service, and its information management environment, Pulse, for use in Lilly's genomics and target validation efforts. Marie Martin, Pangea's director of marketing communications, told BioInform that the sale of the three tools combined optimizes the power of the software maker's core offerings.
GeneWorld is an automated high-throughput analysis application that enables researchers to access, annotate, and analyze large volumes of public and proprietary sequence data. GeneThesaurus is a data subscription service that provides a unified data source from multiple public gene and protein sequence and protein structure databases.
Pangea said Pulse is an information management environment that enables the bioinformatics developer to extend the functionality of an application.
In another deal, Lilly's clinical pharmacology/pharmacokinetic division purchased Pharsight's modeling and analysis software to aid research and development. The pharmaceutical company will deploy Pharsight's WinNonlin-Pro for modeling and analysis in targeted disease areas, including central nervous system and related diseases, endocrine diseases, infectious diseases, cancer, and cardiovascular diseases.
Richard Bergstrom, a senior research scientist for Lilly, said the software's ability to integrate large amounts of data and to provide modeling and analysis based on that information will enable the company to determine more efficiently the rate at which new drugs are absorbed, distributed, and eliminated by the body.